‘How did you work during the shielding period’: 54% worked from home (WFH), prior to COVID-19 only 5% WFH. 2% continued to commute to work.

Conclusion This survey has provided a unique insight into shielding attitudes and behaviours in patients with AIH during the pandemic first wave demonstrating its negative impact on MH and well-being. As further evidence emerges regarding the risk of COVID-19 in adults taking immunosuppressants, more detailed risk stratification may be possible; this would be advantageous from a patient perspective.

END OF LIFE CARE IN PATIENTS WITH CIRRHOSIS: A DISTRICT GENERAL HOSPITAL PERSPECTIVE
Emma Saunsbury*, Daniel Maggs. Royal United Hospitals NHS Foundation Trust, Bath, UK

10.1136/gutjnl-2021-BSG.204

Introduction End of life care (EOLC) refers to care given to patients with a prognosis of <1 year. Whilst cirrhosis-related death can be unforeseen, it typically concludes a prolonged declining clinical trajectory. Clinical encounters therefore represent key opportunities for EOLC planning in this cohort, yet the limitations of current provision by gastroenterologists are increasingly recognised.1 We reviewed our practice to identify areas for improvement.

Methods This retrospective cohort study identified patients who died from sequelae of cirrhosis between January 2018–December 2019 (i.e. pre-COVID) and had >1 non-terminal cirrhosis-related admission in their last year of life. Electronic records were interrogated for evidence of prognostication assessment, transplant candidacy and gastroenterology input. Discussions regarding end-stage liver disease (ESLD), EOLC and palliative care referral were reviewed.

Results 52 patients were identified for analysis. In their last year of life, patients averaged 1.7 cirrhosis-related admissions and 69.2% had >1 outpatient clinic. 61.5% had no prognostication score documented, including 58.3% (7/12) of Child-Pugh C patients. Interestingly, only 23.6% met >3 poor-prognosis criteria prior to their terminal admission.1

ESLD was discussed in a quarter of patients in advance of terminal admission, yet EOLC was subsequently broached in only 61.5% (8/13) of these cases. Just 33.3% of Child-Pugh C patients and 65.3% (17/26) of non-transplantable patients were counselled regarding EOLC. In terms of palliative care provision, 19.2% (10/52) received inpatient palliative care, though 80% of referrals only occurred during their terminal admission. 62.5% of community palliative care referrals occurred in the context of a Continuing Healthcare Fast Track discharge.

Conclusions We have highlighted that more needs to be done to resolve the gaps in our patient pathway to ensure ESLD is recognised, patients are counselled appropriately and fitting EOLC is offered. Enhanced EOLC planning in this high-risk group is a priority, as currently palliative care input is mostly limited to a late stage in the patient journey.

Validated prognostication tools can identify those with poorer prognoses yet, without a formal pathway to review this, patients with declining trajectories were not readily recognised. We plan to introduce an inpatient ‘discharge bundle’ and liver MDT to prompt enhanced follow up of ESLD patients. The goal is to achieve an optimised parallel care model, with earlier EOLC offered alongside ongoing active management in this cohort.

REFERENCE

IGG4 RELATED HEPATOBILIARY DISEASE; EXPERIENCE IN A TERTIARY CENTRE

Introduction IGG4 related hepatobiliary disease (IGG4-HBD) is part of a multisystem fibroinflammatory disorder that can present with abnormal liver function tests alongside symptomatic biliary obstruction, cholangiopathy and pseudo-tumours. We report on the clinical course of a cohort of patients with IGG4-HBD managed in a tertiary hepatobiliary centre.

Methods Consecutive patients with IGG4-HBD over a five year period were retrospectively identified. Patients were diagnosed based on histology, imaging and serum IGG4 levels. Recorded variables included patient demographics, endoscopic procedures and response to therapy.

Results Seventeen patients were identified The median age at diagnosis was 60 years old (28-85 years old). Six (35.3%) presented as a possible malignancy, with pseudo-tumours found in four (23.5%). Four (23.5%) patients had other sites of IGG4 involvement outside the hepatobiliary system. Two cases had established cirrhosis and one had established chronic pancreatitis at diagnosis.

Histology was obtained via Endoscopic Ultrasound (EUS) in 12 (70.6%) patients (one false negative), three (17.6%) via Endoscopic Retrograde Cholangio-pancreatography (ERCP) with biopsies obtained from within the bile duct and two (11.8%) had transcutaneous biopsies. Median IGG4 levels at diagnosis was 5.55 g/L (range 0.73 -12.48 g/L). ERCP was performed on 13 (76.5%) patients prior to induction therapy to relieve biliary obstruction. A straight plastic stent was inserted in one case with the rest having a fully covered self-expanding metal stent (FC-SEMS).

Fifteen (88.2%) patients received Prednisolone for induction. Prednisolone monotherapy was used for maintenance in 8 (47.1%) patients and the same number had dual therapy with Azathioprine. Rituximab was utilized in 3 (17.6%) patients. All of which had been on Prednisolone for a minimum of 2 years and Azathioprine (6 weeks, 2 months and 11 years) before stopping due to severe side effects with subsequent relapse of their IGG4-HBD.

Four (23.5%) were not on maintenance immunosuppression and two (15.4%) patients had stricture resolution with placement of FC-SEMS alone. Patients have been under follow up for a median of 37 months (range 8-144 months). All had marked improvement in biliary strictures following treatment and are currently in remission.

Conclusions We describe a cohort of patient with IGG4 HBD. We show that in this setting EUS guided biopsy alongside ERCP is an effective method of tissue acquisition and that ERCP and biliary drainage can be used as an adjunct to...
medical therapy. Patients with IGG4-HBD respond well to medical therapy and Rituximab can be used effectively in their management.

**PWE-16 INJECTING NETWORK STRUCTURE DETERMINES THE MOST EFFICIENT STRATEGY FOR HEPATITIS C ELIMINATION**

1Ryan Buchanan*, 1Chloe Brown, 2Martin Siegele, 3Rachel Sacks-Davis, 4Mark Wright, 1Salim I Khakoo, 1Julie Parkes. 1Faculty of Medicine, University Of Southampton, Southampton, UK; 2School of Mathematical and Physical Sciences, University of Sussex, Brighton, UK; 3Burnett Institute, Melbourne, Australia; 4Hepatology Department, University Hospital Southampton, Southampton, UK

10.1136/gutjnl-2021-BSG.206

**Introduction** Transmission of Hepatitis C (HCV) continues via sharing of injection equipment between people who inject drugs (PWID). Network-based modelling studies have produced conflicting results as to whether random treatment is preferable to targeting treatment at PWID with multiple partners. We hypothesise that differences in network structure produce this heterogeneity, and aim to test how changing network structure affects HCV transmission and treatment effects.

**Methods** We create three different dynamic injecting network structures connecting 689 PWID (UK-net, AUS-net and USA-net) based on published empirical data. HCV within the networks is transmitted via a susceptible-infected-susceptable model. At 5 years we compare prevalence of HCV in the three networks in three scenarios: 1) with no treatment, 2) with randomly targeted treatment and 3) with treatment targeted at PWID with the most injecting partnerships.

**Results** Median HCV prevalence at 5 years without treatment differed significantly between the three networks (UK-net 42.8%; AUS-net 38.2%, p < 0.0001; USA-net 54.0%, p < 0.0001). In the treatment scenarios UK-net showed a clear benefit of targeted treatment (median 5-year prevalence 1.0% vs. 9.6% vs. p < 0.0001), AUS-net showed a smaller benefit (0.15% vs. 0.44%, p < 0.0001) and USA-net showed no significant difference (29.3% vs. 29.2% random, p = 0.0681). In sensitivity analyses, targeted treatment was optimised in low prevalence, moderate treatment coverage conditions whereas random treatment was optimised in low treatment coverage, high baseline prevalence conditions.

**Conclusions** Network structure determines the transmission rate of HCV in PWID and the most efficient treatment strategy to achieve elimination. In real-world injecting network structures, the benefit of targeting HCV treatment at individuals with multiple injecting partnerships may have been underestimated. Therefore, focussing additional treatment resources at actively injecting PWID who are less engaged with harm reduction may be worthwhile.

**Abstract PWE-16 Figure 1** Box plots showing prevalence of HCV at 5 years, for each network structure from a baseline prevalence of 41.7%: (a) without treatment; (b) treating 6 PWID per month by each of random and degree-based targeted ('network') strategies. The ends of the boxes are the upper and lower quartiles, a horizontal line inside each box marks the median value and the whiskers extend to extreme values at most 1.5x the inter-quartile range. Outliers beyond this range are indicated by crosses.

**PWE-17 PATIENTS WITH HEPATOCELLULAR CARCINOMA HAVE HIGHER RISK AMAP SCORES UP TO 5 YEARS BEFORE DIAGNOSIS**

Benjamin Giles*, Tushar Das, Zeshan Riaz, Joanna Dowman, Andrew Fowell, Richard Aspinall. Portsmouth Hospitals University NHS Trust, Portsmouth, UK

10.1136/gutjnl-2021-BSG.207

**Introduction** Many patients with hepatocellular carcinoma (HCC) are diagnosed too late to be offered potentially curative therapies and there is an unmet need for earlier detection. A recent international study assessed the ‘aMAP’ score (age, male gender, albumin-bilirubin, platelets) for stratifying patients with chronic liver disease into low (<0.2%), medium (0.4-1%) or high (1.6-4%) annual risk of developing HCC [Fan R et al, J Hepatol 2020]. However, the data was predominantly from patients with chronic viral hepatitis recruited in tertiary centres, which may have been subject to referral bias. Consequently, the aim of our study was to assess whether aMAP scoring could have identified patients who developed HCC in an unselected UK population including non-viral liver diseases.

**Methods** A prospectively recorded liver cancer database was used to identify all patients diagnosed with HCC according to EASL-EORTC criteria, over a 10-year period at a major acute